LONG-TERM OUTCOMES WITH EMICIZUMAB PROPHYLAXIS FOR SEVERE HAEMOPHILIA A WITHOUT FVIII INHIBITORS: EFFICACY AND SAFETY ANALYSES FROM HAVEN 3 & 4

被引：0
|
作者：
Mahlangu, J. [1 ,2 ]
Jimenez-Yuste, V. [3 ]
Ventriglia, G. [4 ]
Niggli, M. [4 ]
Barlera, S. [5 ]
Hermans, C. [6 ]
Lehle, M. [4 ]
Chowdary, P. [7 ]
Jew, L. [8 ]
Windyga, J. [9 ]
Frenzel, L. [10 ]
Castaman, G. [11 ]
Pipe, S. W. [12 ]
机构：
[1] Univ Witwatersrand, Johannesburg, South Africa
[2] NHLS, Johannesburg, South Africa
[3] Univ Autonoma Madrid, La Paz Univ Hosp, Madrid, Spain
[4] F Hoffmann La Roche Ltd, Basel, Switzerland
[5] Parexel Int, Milan, Italy
[6] Catholic Univ Louvain UCLouvain, Univ Clin St Luke, Brussels, Belgium
[7] Royal Free London, Katharine Dormandy Haemophilia & Thrombosis Unit, London, England
[8] Genentech Inc, San Francisco, CA USA
[9] Inst Hematol & Transfus Med, Dept Hemostasis Disorders & Internal Med, Lab Hemostasis andMetabol Dis, Warsaw, Poland
[10] Necker Enfants Malades Hosp, Dept Hematol, Paris, France
[11] Careggi Univ Hosp, Florence, Italy
[12] Univ Michigan, Dept Pediat & Pathol, Ann Arbor, MI USA
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO135
引用
收藏
页码：95 / 96
页数：2
相关论文
共 50 条
  • [11] Pharmacokinetics and biomarkers in persons with haemophilia a (PwHA) without FVIII inhibitors receiving emicizumab once weekly in the phase 3 HAVEN 3 study
    Kiialainen, A.
    Schmitt, C.
    Oldenburg, J.
    Callaghan, M.
    Niggli, M.
    Petry, C.
    Castaman, G.
    Shima, M.
    Mahlangu, J.
    Paz-Priel, I.
    Levy, G. G.
    Adamkewicz, J. I.
    HAEMOPHILIA, 2019, 25 : 46 - 47
  • [12] REAL-WORLD EFFICACY OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A WITHOUT INHIBITORS: A REPORT FROM THE UK HAEMOPHILIA CENTRE DOCTORS' ORGANISATION
    Wall, C.
    Xiang, H.
    Palmer, B.
    Collins, P. W.
    Stephensen, D.
    Scott, M.
    Chalmers, E.
    Chowdary, P.
    Hall, G. W.
    Liesner, R.
    Hart, D. P.
    Shapiro, S.
    Talks, K.
    Fletcher, S.
    Hay, C. R.
    HAEMOPHILIA, 2021, 27 : 116 - 116
  • [13] EMICIZUMAB PROPHYLAXIS IN SEVERE HAEMOPHILIA A WITHOUT INHIBITORS: OUTCOME AND INDICATIONS. FROM THE UK HAEMOPHILIA CENTRE DOCTORS' ORGANISATION
    Hay, C. R. M.
    Wall, C.
    Xiang, H.
    Palmer, B.
    Chowdary, P.
    Collins, P.
    Fletcher, S.
    Hall, G. W.
    Mathias, M.
    Percy, C.
    Sartain, P.
    Susan, S.
    Stephensen, D.
    Talks, K.
    HAEMOPHILIA, 2022, 28 : 50 - 51
  • [14] EMICIZUMAB PROPHYLAXIS IN SEVERE HAEMOPHILIA A WITHOUT INHIBITORS: OUTCOME AND INDICATIONS. FROM THE UK HAEMOPHILIA CENTRE DOCTORS' ORGANISATION
    Hay, C.
    Wall, C.
    Xiang, H.
    Palmer, B.
    Chowdary, P.
    Collins, P.
    Fletcher, S.
    Mathias, M.
    Percy, C.
    Sartain, P.
    Shapiro, S.
    Stephensen, D.
    Talks, K.
    HAEMOPHILIA, 2023, 29 : 78 - 79
  • [15] Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors
    Shima, Midori
    Hanabusa, Hideji
    Taki, Masashi
    Matsushita, Tadashi
    Sato, Tetsuji
    Fukutake, Katsuyuki
    Kasai, Ryu
    Yoneyama, Koichiro
    Yoshida, Hiroki
    Nogami, Keiji
    BLOOD ADVANCES, 2017, 1 (22) : 1891 - 1899
  • [16] Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study
    Kiialainen, Anna
    Niggli, Markus
    Kempton, Christine L.
    Castaman, Giancarlo
    Chang, Tiffany
    Paz-Priel, Ido
    Adamkewicz, Joanne, I
    Levy, Gallia G.
    HAEMOPHILIA, 2022, 28 (06) : 1033 - 1043
  • [17] Surgical procedures in persons with haemophilia A (PWHA) without inhibitors receiving emicizumab - Experience from the HAVEN 3 study
    Santagostino, E.
    Parnes, A.
    Dhalluin, C.
    Oldenburg, J.
    Niggli, M.
    Lambert, T.
    Kempton, C.
    Ko, R. H.
    Han, J. W.
    Wozny, T.
    Paz-Priel, I.
    Levy, G. G.
    Mahlangu, J.
    HAEMOPHILIA, 2019, 25 : 33 - 33
  • [18] EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH MILD OR MODERATE HAEMOPHILIA A WITHOUT FACTOR VIII INHIBITORS: RESULTS FROM THE INTERIM ANALYSIS OF THE HAVEN 6 STUDY
    Negrier, C.
    Mahlangu, J.
    Lehle, M.
    Chowdary, P.
    Catalani, O.
    Jimenez-Yuste, V.
    Beckermann, B. M.
    Schmitt, C.
    Hermans, C.
    Ventriglia, G.
    Windyga, J.
    Kiialainen, A.
    d'Oiron, R.
    Moorehead, P.
    Teodoro, V.
    Shapiro, A.
    Oldenburg, J.
    HAEMOPHILIA, 2022, 28 : 20 - 21
  • [19] EFFICACY/SAFETY IN CHILDREN ON 2/4-WEEKLY EMICIZUMAB PROPHYLAXIS: 52-WEEK OUTCOMES IN HAVEN 2
    Young, Guy
    Sidonio, Robert, Jr.
    Oldenburg, Johannes
    Jimenez-Yuste, Victor
    Mahlangu, Johnny
    Kruse-Jarres, Rebecca
    Wang, Michael
    Shima, Midori
    Tzeng, Eunice
    Ko, Richard
    Bernardi, Ronald
    Fox, Richard
    Mancuso, Maria Elisa
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [20] Factor VIII use in the treatment of breakthrough bleeds in persons with haemophilia a without inhibitors on emicizumab prophylaxis: the phase III HAVEN 3 study experience
    Callaghan, M.
    Trzaskoma, B.
    Ko, R.
    Lee, L.
    Patel, A.
    Tzeng, E.
    Shah, M.
    Chang, T.
    Niggli, M.
    Dhalluin, C.
    Paz-Priel, I.
    Mahlangu, J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 : 44 - 45
12345